Mevidalen Alzheimer's trial infographic: PRESENCE-ALZ Phase 2 results

Eli Lilly’s mevidalen Alzheimer’s trial has failed: in the 304-patient Phase 2 PRESENCE-ALZ study, presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston on 16 to 19 November 2026, neither the 25 mg nor the 50 mg daily dose improved cognition and daily function over placebo after 24 weeks. Lilly concluded that the results did not support a meaningful clinical benefit from boosting dopamine D1 signalling, and trade press reports say the company is dropping the Alzheimer’s programme.

The result matters because mevidalen was one of the few late-stage attempts to treat Alzheimer’s symptoms through a new brain chemistry pathway, rather than by clearing amyloid or tau. Its failure leaves symptomatic treatment where it has been for two decades, centred on older cholinesterase inhibitors and memantine.

Key takeaways on the mevidalen Alzheimer’s trial

  • PRESENCE-ALZ (NCT06538116) randomised 304 adults with mild-to-moderate Alzheimer’s in the US and Japan to placebo, mevidalen 25 mg or mevidalen 50 mg once daily for 24 weeks.
  • The primary endpoint, change on the integrated Alzheimer’s Disease Rating Scale (iADRS), needed a greater than 60% probability of at least a 2-point benefit. The trial reached only 14.0% (25 mg) and 21.2% (50 mg).
  • Secondary cognitive, functional and behavioural measures showed no consistent benefit; one global rating nominally favoured placebo.
  • Side effects were similar to placebo overall, with no deaths and no major cardiovascular events, but systolic blood pressure rose about 8 to 11 mm Hg after dosing.
  • Mevidalen had already missed its primary endpoint in a Phase 2 study in Lewy body dementia.

How the trial was designed

PRESENCE-ALZ was led by Lilly neurologist Adam Fleisher and presented as a poster at CTAD 2026, with details reported by NeurologyLive. The trial registration is available on ClinicalTrials.gov (NCT06538116).

Participants were aged 50 to 80, had Alzheimer’s pathology confirmed by a plasma p-tau217 blood test or earlier biomarker results, had at least six months of gradual decline affecting everyday life, and scored 13 to 24 on the Mini-Mental State Examination. That range covers mild-to-moderate disease, a broader and more advanced group than the early-stage patients typically enrolled in amyloid antibody trials.

Patients were split evenly across three arms, roughly 101 per group (by our calculation). Doses were titrated up, and anyone with a potentially significant change in blood pressure or pulse during titration had treatment stopped permanently.

The results in numbers

Lilly used a Bayesian analysis, which asks how likely the drug is to have produced a meaningful effect rather than simply testing for a p-value. The bar was a more than 60% probability that either dose delivered at least a 2-point advantage on the iADRS, a 144-point combined scale of thinking and daily function.

Endpoint at week 24Mevidalen 25 mgMevidalen 50 mgTarget
Probability of at least 2-point iADRS benefit14.0%21.2%Above 60%
Difference vs placebo on iADRS (points)0.62 (95% CI -2.27 to 3.50)0.95 (95% CI -1.95 to 3.86)At least 2
Any treatment-emergent adverse event65.1%62.5%Placebo: 65.7%
Serious adverse events9.4%5.2%Placebo: 5.9%

Both confidence intervals cross zero, so the trial cannot rule out no effect at all. Among secondary measures, which included the ADAS-Cog, MMSE, verbal fluency, daily-living scales and a neuropsychiatric inventory, the only nominally significant result was on the Quick Dementia Rating System, where the 50 mg arm did worse than placebo by about one point. Researchers did not find supporting signals elsewhere, so that finding is likely noise.

Why Lilly bet on dopamine

Mevidalen is a positive allosteric modulator of the dopamine D1 receptor. Instead of switching the receptor on directly, it amplifies the brain’s own dopamine signal at that receptor. Dopamine signalling in the prefrontal cortex, which supports attention, working memory and planning, is reduced in Alzheimer’s. The theory was that a modulator could improve these functions without the over-stimulation and loss of effect seen with direct D1 agonists.

The approach had struggled before. In the earlier PRESENCE trial in Lewy body dementia, published in Movement Disorders in 2022, mevidalen missed its main cognitive endpoint, though it showed hints of benefit on global impression, movement symptoms and daytime sleepiness, mostly at a 75 mg dose. That dose was later dropped after four serious cardiovascular events, and blood pressure increases persisted at higher doses. The Alzheimer’s study tested lower doses, and the blood pressure signal still appeared.

Safety: what doctors will note

Overall adverse event rates were close to placebo, mostly infections, abnormal lab results and stomach upsets. There were no deaths and no major adverse cardiovascular events. The concern is blood pressure: in both mevidalen groups, systolic pressure rose roughly 8 to 11 mm Hg in the four hours after doses during titration visits. Many people with Alzheimer’s are older adults who already have hypertension or heart disease, so a symptomatic drug with that profile would have needed a clear benefit to justify it.

What this means for Alzheimer’s treatment

The CTAD meeting this year was otherwise dominated by disease-modifying approaches. Biogen’s tau-lowering drug diranersen showed a 38% slowing of decline at two years (see our diranersen results report), while AriBio’s oral AR1001 missed its overall Phase 3 goal but showed a subgroup signal (covered in our AR1001 POLARIS-AD analysis). Lilly’s own Alzheimer’s portfolio is anchored by Kisunla (donanemab), an amyloid-clearing antibody.

Mevidalen’s failure is a reminder that improving symptoms in established Alzheimer’s remains hard. For patients and families in India and elsewhere, standard care for mild-to-moderate disease is unchanged: cholinesterase inhibitors such as donepezil, memantine for moderate-to-severe stages, and management of blood pressure, sleep, hearing and mood.

Market context

Acumen Research and Consulting’s Alzheimer’s disease treatment market report projected the global market to reach around USD 5.65 billion by 2027, growing at about 12.8% a year from 2020, and found that cholinergic drugs held the largest share by drug class. That forecast window started before the first amyloid antibodies reached the market, so the figures are best treated as indicative. Acumen also cites US estimates that the number of Americans with Alzheimer’s could rise to about 14 million by 2060, underlining the demand that keeps companies testing new mechanisms despite setbacks like this one.

Frequently asked questions

What is mevidalen?

Mevidalen (LY3154207) is an experimental oral drug from Eli Lilly that boosts the brain’s response to dopamine at the D1 receptor. It was tested as a symptomatic treatment for Alzheimer’s disease and Lewy body dementia.

Did mevidalen work for Alzheimer’s disease?

No. In the Phase 2 PRESENCE-ALZ trial of 304 patients, neither dose produced a meaningful improvement over placebo on the iADRS measure of cognition and daily function after 24 weeks.

Is mevidalen safe?

Overall side-effect rates were similar to placebo, with no deaths or major cardiovascular events, but the drug raised systolic blood pressure by about 8 to 11 mm Hg after dosing.

Will Lilly continue developing mevidalen?

Lilly said the data did not support a significant clinical benefit from D1 dopamine potentiation, and industry reports say the Alzheimer’s programme is being discontinued. Lilly has not announced any further trials in Alzheimer’s.

Sources: PRESENCE-ALZ poster, CTAD 2026, as reported by NeurologyLive (18 Nov 2026); ClinicalTrials.gov NCT06538116; Biglan et al., Movement Disorders 2022. Market data: Acumen Research and Consulting. This article is for information only and is not medical advice. Last updated 20 November 2026.

More clinical trials news: Clinical Trials

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *